Role of Verapamil in Treating Premature Ventricular Contractions and Premature Atrial Contractions

Mechanism of Action and Efficacy

Verapamil is a calcium channel blocker that works by slowing conduction through the AV node and increasing AV node refractoriness, making it effective for arrhythmias involving the AV node, according to the American College of Cardiology 1
Verapamil's mechanism makes it particularly effective for arrhythmias involving the AV node, as stated by the British Journal of Sports Medicine, although the specific context is not provided 2

The American College of Cardiology recommends verapamil as a first-line treatment alongside beta-blockers for patients with symptomatic PVCs in an otherwise normal heart 1
Verapamil has limited evidence supporting its use specifically for isolated PACs, and it may reduce heart rate during PAC episodes but does not significantly reduce PAC frequency, as reported in Circulation 3

The American College of Cardiology states that verapamil is highly effective for a specific type of ventricular tachycardia called verapamil-sensitive idiopathic left ventricular tachycardia (interfascicular reentry) 1
For sustained hemodynamically tolerated verapamil-sensitive idiopathic LVT, intravenous verapamil is recommended for VT termination by the American College of Cardiology 1
The European Heart Journal suggests that intravenous verapamil should be considered to acutely suppress or prevent electrical storm or recurrent ICD discharges in patients with short-coupled torsade de pointes 4

The British Journal of Sports Medicine recommends an intravenous administration dose of 5-10 mg over 60 seconds for acute settings 2

The British Journal of Sports Medicine states that verapamil is contraindicated in patients who have taken beta-blockers due to risk of profound bradycardia and hypotension 2
Verapamil should not be used in patients with Wolff-Parkinson-White syndrome with atrial fibrillation/flutter, as contraindicated by the British Journal of Sports Medicine 2
The American College of Cardiology and other guidelines contraindicate verapamil in patients with significant left ventricular dysfunction, increased risk for cardiogenic shock, and second or third-degree AV block without a cardiac pacemaker, although the specific guideline society is not provided 5

The American College of Cardiology recommends beta-blockers or non-dihydropyridine calcium channel blockers (including verapamil) as first-line therapy for symptomatic PVCs in structurally normal hearts 1
For verapamil-sensitive idiopathic LVT, the American College of Cardiology recommends intravenous verapamil for acute termination and oral verapamil for chronic management 1

The American Heart Association recommends assuming ventricular origin until proven otherwise when encountering a patient with potential R-on-T phenomenon, and advises against administering verapamil for diagnostic purposes in patients with wide-complex tachycardia, instead using DC cardioversion or appropriate antiarrhythmics like amiodarone or procainamide 6
The American College of Cardiology suggests reserving verapamil only for confirmed supraventricular arrhythmias in hemodynamically stable patients without structural heart disease, with a strong recommendation based on high-quality evidence 7, 8

In patients with supraventricular tachycardia, the American Heart Association recommends using verapamil only when the diagnosis is definitively confirmed, such as in cases of AVNRT, AVRT without pre-excitation, or multifocal atrial tachycardia, with a moderate recommendation based on moderate-quality evidence 7